A multi-center, non-randomized control clinical trial for Gemcitabine and Oxaliplatin combined with Sorafenib for HCC.
Phase of Trial: Phase II
Latest Information Update: 21 May 2012
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 21 May 2012 Planned End Date changed from 1 Mar 2013 to 1 Sep 2014 as reported by Chinese Clinical Trial Register record.
- 22 Sep 2011 New trial record